Russian Heart Failure Journal 2010year Acetazolamide in cardiology practice: clinical experience and evidence base

To access this material please log in or register

Register Authorize

Acetazolamide in cardiology practice: clinical experience and evidence base

Gilyarevskiy S. R., Orlov V. A., Golshmid M. V., Zakharova G. Y., Sinitsina I. I.

Keywords: acetazolamide, chronic obstructive pulmonary disease, CHF, central sleep apnea

DOI: 10.18087/rhfj.2010.6.1443

This review presents possible indications for acetazolamide prescription. It is used in CHF in order to overcome resistance to loop diuretics, for treatment of central sleep apnea. The beneficial effect of acetazolamide on blood gas composition is shown in patients with hypercapnia due to COPD. Acetazolamide is effective for prevention of cardiovascular complications of high-altitude illness. Test with acetazolamide is used for assessment of cerebral blood flow. However, to refine the tactics of acetazolamide usage, as well as other diuretics in CVD treatment, randomized clinical trials conducting is necessary.
  1. Hanley T, Platts MM. Acetazolamide (diamox) in the treatment of congestive heart-failure. Lancet. 1956;270 (6919):357–359.
  2. Терлецкая Т. М. Использование диакарба при недостаточности кровообращения. Клиническая медицина. 1958;36:129–131.
  3. Laurence DR. Clinical Pharmacology. 4‑th Ed. Edinburgh 1973, London, New Work: Chruchill: Livingstone, p. 400.
  4. Stewart W. C. Perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol 1999;10:99–108.
  5. Stewart CE. Anticonvulsant medications. Emerg Med Serv. 2001;30 (7):56–66.
  6. Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 2002;24 (3):150–154.
  7. Tso E. High-altitude illness. Emerg Med Clin North Am. 1992 May; 10 (2):231–247.
  8. Dumont L, Tramer M. R, Lysakowski C et al. Efficacy of low-dose acetazolamide for the prophylaxis of acute mountain sickness. High Alt Med Biol 2003;4 (3):45–52.
  9. Мареев В. Ю. Диуретики в терапии сердечной недостаточности. Сердечная недостаточность. 2001;2 (1):11–20.
  10. Wagenaar M, Vos P, Heijdra Y et al. Comparison of acetazolamide and medroxyprogesterone as respiratory stimulants in hypercapnic patients with COPD. Chest. 2003;123 (5):1450–1459.
  11. Links TP, Smit AJ, Molenaar WM et al. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci. 1994;122 (1):33–43.
  12. Baran DA, Gomberg-Maitland M. Confronting heart failure in the ICU: The treatment challenge; Signs and symptoms guide the treatment. J Critical Illness. 2002. Available at:
  13. Mazur JE, Devlin JW, Peters MJ et al. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med. 1999;27 (7):1257–1261.
  14. Pickkers P, Hughes AD, Russel FG et al. In vivo evidence for K (Ca) channel opening properties of acetazolamide in the human vasculature. Br J Pharmacol. 2001;132 (2):443–450.
  15. Karnik R, Valentin A, Winkler WB et al. Sex-Related Differences in Acetazolamide-Induced Cerebral Vasomotor Reactivity. Stroke. 1996;27 (1):56–58.
  16. Knauf H, Mutschler E. Functional state of the nephron and diuretic dose-response-rationale for low-dose combination therapy. Cardiology. 1994;84 (Suppl 2):18–26.
  17. Jackson ER. Diuretics. In: Hardman J. G, Limbird L. E, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill Medical Publishing Division; 2001:757–787.
  18. Ravnan SL, Ravnan MC, Deedwania PC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail. 2002;8 (2):80–85.
  19. De Bruyne LK. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003;79 (931):268–271.
  20. Neuberg GW, Miller AB, O’Connor CM et al. Diuretic Resistance Predicts Mortality in Patients With Advanced Heart Failure. Am Heart J. 2002;144 (1):31–38.
  21. Epstein M, Lepp BA, Hoffman DS et al. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res. 1977;21:656–667.
  22. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29 (3):367–372.
  23. Brater DC. Diuretic therapy. N Engl J Med. 1998;339 (6):387–395.
  24. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1985;233 (2):447–453.
  25. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol. 1993;3 (12):1878–1883.
  26. Wakelkamp M, Alván G, Gabrielsson J, Paintaud G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther. 1996;60 (1):75–88.
  27. Kelly RA, Wilcox CS, Mitch WE et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int. 1983;24 (2):233–239.
  28. Wilcox CS, Guzman NJ, Mitch WE et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int. 1987;31 (1):135–141.
  29. Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol. 1988;255 (6 Pt 2):F1256–1268.
  30. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol. 1988;255 (6 Pt 2):F1269–1275.
  31. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 1989;83 (1):113–126.
  32. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36 (4):682–689.
  33. Kobayashi S, Clemmons DR, Nogami H et al. Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Kidney Int. 1995;47 (3):818–828.
  34. Olesen KH, Sigurd B. The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide dur-ing long-term treatment with furosemide and spironolactone: permutation trial tests in patients with congestive heart failure. Acta Med Scand. 1971;190 (3):233–240.
  35. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resis-tance. Ann Intern Med. 1991;114 (10):886–894.
  36. Sica DA, Gehr T. W. B. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30 (3):229–249.
  37. Maren TH. Carbonic anhydrase inhibition. IX. Augmentation of the renal effect of merallu-ride by acetazolamide. J Pharmacol Exp Ther. 1958;123 (4):311–315.
  38. Gibson DG, Marshall JC, Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J. 1970;32 (3):399–405.
  39. Earley LE, Martino JA. Influence of sodium balance on the ability of diuretics to inhibit tubular reabsorption: a study of factors that influence renal tubular sodium reabsorption in man. Circulation. 1970;42 (2):323–334.
  40. Rodicio JL, Hernando L. Effects and interactions of furosemide and acetazolamide on tubular function in rat kidney. Rev Esp Fisiol. 1977;33 (2):113–118.
  41. Sackner-Bernstein JD, Obeleniene R. How should diuretic-refractory, volume-overloaded heart failure patients be managed? J Invasive Cardiol. 2003;15 (10):585–590.
  42. Brater DC, Kaojarern S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and aceta-zolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther. 1983;227 (1):92–97.
  43. Khan MI. Treatment of refractory congestive heart failure and normokale­mic hypochlore-mic alkalosis with acetazolamide and spironolactone. Can Med Assoc J. 1980;123 (9):883–887.
  44. Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. Chest. 2001;119 (3):807–810.
  45. Wisskirchen T, Teschler H. Central sleep apnea syndrome and Cheyne-Stokes respiration. Ther Umsch. 2000;57 (7):458–462.
  46. Javaheri S, Parker TJ, Wexler L et al. Effects of theophylline on sleep-disordered breath-ing in stable heart failure. N Engl J Med. 1996;335 (8):562–567.
  47. Javaheri S, Colangelo G, Lacey W, Gartside PS. Chronic hypercapnia in obstructive sleep apnea syndrome. Sleep. 1994;17 (5):416–423.
  48. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep. 1992;15 (2):173–184.
  49. Javaheri S, Parker TJ, Wexler L et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med. 1995;122 (7):487–492.
  50. Quaranta AJ, D’Alonzo GE, Krachman SL. Cheyne-Stokes respiration du­ring sleep in congestive heart failure. Chest. 1997;111 (2):467–473.
  51. Javaheri S, Parker TJ, Liming JD et al. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequen­ces, and presentations. Circulation. 1998;97 (21):2154–2159.
  52. Burgess KR. Central sleep apnoea and heart failure (Part I). Respirology. 1997;2 (4):243–253.
  53. Javaheri S, Corbett WS. Association of low PaCO2 with central sleep apnea and ventricular arrhythmias in ambulatory patients with stable heart failure. Ann Intern Med. 1998;128 (3):204–207.
  54. Hudgel DW, Thanakitcharu S. Pharmacologic treatment of sleep-disordered breathing. Am J Respir Crit Care Med. 1998;158 (3):691–699.
  55. Burgess KR. Central sleep apnoea and heart failure (Part II). Respirology. 1998;3 (1):1–11.
  56. DeBacker WA, Verbraecken J, Willemen M et al. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med. 1995;151 (1):87–91.
  57. Findley LJ, Blackburn MR, Goldberger AL, Mandell AJ. Apneas and oscillation of cardiac ectopy in Cheyne-Stokes breathing during sleep. Am Rev Respir Dis. 1984;130 (5):937–939.
  58. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double – blind, prospective study. Am J Respir Crit Care Med. 2006;173 (2):234–237.
  59. Severinghaus JW. Acetazolamide and respiration: theory and uses. Int Crit Care Digest. 1990;9:32–34.
  60. Travis DM, Wiley C, Nechay BR, Maren TH. Selective renal carbonic anhydrase inhibition without respiratory effect: pharmacology of 2‑benzene-sulfonamido-1,3,4‑thiadizole-5‑sulfonamide (CL 11,366). J Pharmacol Exp Ther. 1964;143:383–394.
  61. Swenson ER, Leatham KL, Roach RC et al. Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing. Respir Physiol. 1991;86 (3):333–343.
  62. Teppema LJ, Dahan A. Acetazolamide and breathing. Does a clinical dose alter peripheral and central CO (2) sensitivity? Am J Respir Crit Care Med. 1999;160 (5 Pt 1):1592–1597.
  63. Jones P. W, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstruc-tive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.
  64. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 1993;328 (14):1017–1022.
  65. Brijker F, Heijdra YF, van den Elshout FJ, Folgering HT. Discontinuation of furosemide decreases PaCO (2) in patients with COPD. Chest. 2002;121 (2):377–382.
  66. Dickinson GE, Myers ML, Goldbach M, Sibbald W. Acetazolamide in the treatment of ventilatory failure complicating acute metabolic alkalosis. Anesth Analg. 1981;60 (8):608–610.
  67. THE MERCK MANUAL, Sec_ 20, Ch_ 281, Altitude Sickness. Available at:
  68. Voelkel NF. High-altitude pulmonary edema. N Engl J Med. 2002;346 (21):1606–1607.
  69. Burki NK, Khan SA, Hameed MA. The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest. 1992;101 (3):736–741.
  70. Gertsch JH, Basnyat B, Johnson EW et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328 (7443):797.
  71. Bradwell AR, Dykes PW, Coote JH et al. Effect of acetazolamide on exercise perfor-mance and muscle mass at high altitude. Lancet. 1986;1 (8488):1001–1005.
  72. Ritschel WA, Paulos C, Arancibia A et al. Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol. 1998;38 (6):533–539.
  73. Naeije R, Mélot C. Acute pulmonary oedema on the Ruwenzori mountain range. Br Heart J. 1990;64 (6):400–402.
  74. Frankel HM, Garcia E, Malik F et al. Effect of acetazolamide on cerebral blood flow and capillary patency. J Appl Physiol. 1992;73 (5):1756–1761.
  75. Petrella JR, DeCarli C, Dagli M et al. Age-related vasodilatory response to acetazolamide challenge in healthy adults: a dynamic contrast-enhanced MR study. AJNR Am J Neuroradiol. 1998;19 (1):39–44.
  76. Kiss B, Dallinger S, Findl O et al. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am J Physiol. 1999;276 (6 Pt 2):R1661–1667.
  77. Eicke BM, Buss E, Bähr RR et al. Influence of Acetazolamide and CO2 on Extracranial Flow Volume and Intracranial Blood Flow Velocity. Stroke. 1999;30 (1):76–80.
  78. Hojer-Pedersen E. Effect of acetazolamide on cerebral blood flow in subacute and chronic cerebrovascular disease. Stroke. 1987;18 (5):887–891.
  79. Piepgras A, Schmiedek P, Leinsinger G et al. A simple test to assess cerebrovascular reserve capacity using transcranial Doppler sonography and acetazolamide. Stroke. 1990;21 (9):1306–1311.
  80. Dahl A, Lindegaard KF, Russell D et al. A comparison of transcranial Doppler and cerebral blood flow studies to assess cerebral vasoreactivity. Stroke. 1992;23 (1):15–19.
  81. Okudaira Y, Bandoh K, Arai H, Sato K. Evaluation of the acetazolamide test: vasoreactivity and cerebral blood volume. Stroke. 1995;26 (7):1234–1239.
  82. Dahl A, Russell D, Rootwelt K et al. Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood flow measurements: dose, serum concentration, and time course of the response to acetazo­lamide. Stroke. 1995;26 (12):2302–2306.
  83. Schmiedek P, Piepgras A, Leinsinger G et al. Improvement of cerebrovascular reserve capacity by EC–IC arte-rial bypass surgery in patients with ICA occlusion and hemodynamic cerebral ischemia. J Neurosurg. 1994;81 (2):236–244.
  84. Kleiser B, Widder B. Course of carotid artery occlusions with impaired cerebrovascular reactivity. Stroke. 1992;23 (2):171–174.
  85. Chimowitz MI, Furlan AJ, Jones SC et al. Transcranial Doppler assessment of cerebral perfusion reserve in patients with carotid occlusive disease and no evidence of cerebral infarction. Neurology. 1993;43 (2):353–357.
  86. Kuroda S, Kamiyama H, Abe H et al. Acetazolamide test in detecting reduced cerebral perfusion reserve and predicting long-term prognosis in patients with internal carotid artery occlusion. Neurosurgery. 1993;32 (6):912–918.
  87. Yonas H, Smith HA, Durham SR et al. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg. 1993;79 (4):483–489.
  88. Schreiber SJ, Gottschalk S, Weih M et al. Assessment of blood flow velocity and diameter of the middle cerebral artery during the acetazolamide provocation test by use of transcranial Doppler sonography and MR imaging. AJNR Am J Neuroradiol. 2000;21 (7):1207–1211.
  89. Kuwabara Y, Ichiya Y, Sasaki M et al. Time dependency of the acetazolamide effect on cerebral hemodynamics in patients with chronic occlusive cerebral arteries. Early steal phenomenon demonstrated by [15O] H2O positron emission tomography. Stroke. 1995;26 (10):1825–1829.
  90. Chapron DJ, Gomolin IH, Sweeney KR. Acetazolamide blood concentrations are excessive in the elderly: pro-pensity for acidosis and relationship to renal function. J Clin Pharmacol. 1989;29 (4):348–353.
  91. Egge K, Zahl PH. Survival of glaucoma patients. Acta Ophthalmol Scand. 1999;77 (4):397–401.
  92. Lee YT, Wu JC, Chan FK. Acetazolamide-induced Gerstmann syndrome. Int J Clin Pract. 1999;53 (7):560–561.
  93. Anderson CJ, Kaufman PL, Sturm RJ. Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthalmol. 1978;86 (4):516–519.
  94. Sweeney KR, Chapron DJ, Brandt JL et al. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther. 1986;40 (5):518–524.
  95. Parks JP, Ruml LA, Pak CYC. Hypocitraturia. In: Coe FL, Favus M, Pak CYC, eds. Kidney stones: medical and surgical management. Philadelphia: Lippincott-Raven, 1996:905–920.
  96. Kurz M. Diamox and manifestation of diabetes mellitus. Wien Med Wochenschr. 1968;118 (11):239–241.
Gilyarevskiy S. R., Orlov V. A., Golshmid M. V. et al. Acetazolamide in cardiology practice: clinical experience and evidence base. Russian Heart Failure Journal. 2010;11(6):375-381.

To access this material please log in or register

Register Authorize
Ru En